Eli Lilly Patent-Cliff Exposure & CMS Drug Spending Portfolio

Eli Lilly (Indianapolis, IN): 68 reconciled FDA prescription therapies, $22.45B 2024 CMS Part D & Medicaid spend, and 27 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterIndianapolis, IN
Reconciled FDA Portfolio Therapies68
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$22.45B
2024 Medicare Part D Spend$16.73B
2024 Medicaid Spend$5.73B
California HCAI SB 17 Filings27 WAC filings (max 1428.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.